Roivant Sciences Ltd.
ROIV
$11.31
-$0.05-0.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -98.75% | -97.64% | 882.87% | 638.83% | 577.05% |
| Total Depreciation and Amortization | -32.33% | 146.71% | 92.87% | 31.94% | 71.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 89.57% | 90.01% | -2,963.98% | -2,182.98% | -1,772.86% |
| Change in Net Operating Assets | -1,225.11% | -403.35% | -33.88% | -431.01% | 49.33% |
| Cash from Operations | 25.17% | 39.16% | 39.66% | 15.82% | 9.26% |
| Capital Expenditure | -225.47% | -314.38% | -83.21% | 58.40% | 90.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -95.62% | -97.06% | 169,384.76% | 78,128.51% | 78,128.51% |
| Other Investing Activities | 15,053.60% | 60,834.06% | 1,255.87% | 105.79% | 106.13% |
| Cash from Investing | -70.65% | -91.34% | 7,008.94% | 14,273.96% | 11,854.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -120.10% | -278.70% | -12.64% | 23.99% | -4.65% |
| Issuance of Common Stock | 29.18% | 13.82% | -87.27% | -87.27% | -64.78% |
| Repurchase of Common Stock | -3,127.87% | -10,298.05% | -10,007.72% | -10,007.72% | -298.96% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -52.76% | -100.00% | 252.49% | 252.49% | 264.61% |
| Cash from Financing | -364.86% | -245.88% | -178.70% | -168.15% | -16.04% |
| Foreign Exchange rate Adjustments | -307.54% | -259.38% | -372.65% | -372.65% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -103.30% | -119.81% | 2,353.86% | 937.31% | 1,372.09% |